Pharmaceutics · 2 authors, 1 centre
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This preclinical study evaluated a novel non-invasive ocular delivery platform (NIODP) applied to the periorbital skin in non-human primates and rabbits. The platform efficiently delivered the drug candidate JV-MD2 (DHA) to both the anterior and posterior segments of the eye, achieving a retinal Cmax of 111 µg/g.
The study describes the development and evaluation of a novel non-invasive ocular delivery platform (NIODP) for topical administration via the periorbital skin. The platform was tested in a non-human primate model for JV-MD2 (omega-3 DHA) and in rabbits and non-human primates for the anti-inflammatory agent JV-DE1. The central result is that a single NIODP dose of about 7 mg JV-MD2 achieved a Cmax of 111 µg/g in the retina and 66 µg/g in the cornea of non-human primates. For JV-DE1, NIODP delivered the drug to the anterior segment as efficiently as eye drops, but retinal delivery was about 10-fold lower than with eye drops. The paper proposes that drugs may be transported via the corneal pathway to the anterior segment and via the conjunctiva/sclera pathway to the posterior segment. Limitations include the preclinical nature of the studies in animal models, with no direct human trials reported, and different species were used for comparative eye drop and NIODP studies for JV-DE1. The implications suggest the platform has potential for non-invasive retinal drug delivery, potentially avoiding ocular irritation and injections.
